Sign In
Buy VRCA
$5.22
-0.0400 (-0.760%)
At Close: Jul 31, 2026
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceutic
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceutic
Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript
11:22am, Wednesday, 11'th Mar 2026
Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
08:00am, Wednesday, 11'th Mar 2026
– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
08:00am, Thursday, 05'th Mar 2026
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medica
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of “Moderate Buy” by Brokerages
03:18am, Thursday, 26'th Feb 2026
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six analysts that are currently covering the firm, MarketBeat reports. O
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
08:00am, Monday, 23'rd Feb 2026
WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin disease
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
08:00am, Thursday, 12'th Feb 2026
WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin disease
WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin disease
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why
01:00pm, Monday, 02'nd Feb 2026
Verrica Pharmaceuticals (VRCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for February 2nd
07:01am, Monday, 02'nd Feb 2026
LUV, VRCA, CVLT, FINW and SDVKY have been added to the Zacks Rank #1 (Strong Buy) List on February 2, 2026.
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update
02:27am, Tuesday, 20'th Jan 2026
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA - Get Free Report) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totali
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%
10:55am, Monday, 12'th Jan 2026
The mean of analysts' price targets for Verrica Pharmaceuticals (VRCA) points to a 97.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $17.00 Consensus Target Price from Brokerages
02:04am, Saturday, 10'th Jan 2026
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA - Get Free Report) has been assigned a consensus rating of "Hold" from the five analysts that are currently covering the firm, Marketbeat Ratings reports. On
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
08:00am, Wednesday, 07'th Jan 2026
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market oppo
